DK2822965T3 - FREMGANGSMÅDE TIL BERIGELSE AF IgA - Google Patents

FREMGANGSMÅDE TIL BERIGELSE AF IgA Download PDF

Info

Publication number
DK2822965T3
DK2822965T3 DK13708164.2T DK13708164T DK2822965T3 DK 2822965 T3 DK2822965 T3 DK 2822965T3 DK 13708164 T DK13708164 T DK 13708164T DK 2822965 T3 DK2822965 T3 DK 2822965T3
Authority
DK
Denmark
Prior art keywords
iga
enrichment
procedure
Prior art date
Application number
DK13708164.2T
Other languages
English (en)
Inventor
Menyawi Ibrahim El
Marius Loetscher
Doreen Siegemund
Original Assignee
Csl Behring Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Ag filed Critical Csl Behring Ag
Application granted granted Critical
Publication of DK2822965T3 publication Critical patent/DK2822965T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
DK13708164.2T 2012-03-09 2013-03-08 FREMGANGSMÅDE TIL BERIGELSE AF IgA DK2822965T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12158927.9A EP2636681A1 (en) 2012-03-09 2012-03-09 Process for enriching IgA
PCT/EP2013/054698 WO2013132053A1 (en) 2012-03-09 2013-03-08 Process for enriching iga

Publications (1)

Publication Number Publication Date
DK2822965T3 true DK2822965T3 (da) 2022-07-11

Family

ID=47843296

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13708164.2T DK2822965T3 (da) 2012-03-09 2013-03-08 FREMGANGSMÅDE TIL BERIGELSE AF IgA

Country Status (9)

Country Link
US (1) US9828418B2 (da)
EP (2) EP2636681A1 (da)
JP (1) JP6259777B2 (da)
KR (1) KR102079487B1 (da)
CN (1) CN104245728B (da)
AU (1) AU2013201388B2 (da)
DK (1) DK2822965T3 (da)
ES (1) ES2919861T3 (da)
WO (1) WO2013132053A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014022240A2 (pt) 2012-03-09 2017-08-01 Csl Behring Ag composições compreendendo imunoglobulinas semelhantes à secretoras
EP2636684A1 (en) * 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
US10144774B2 (en) * 2013-07-01 2018-12-04 Csl Behring Ag Method for purifying IgG
GB201413227D0 (en) 2014-07-25 2014-09-10 Bioproducts Lab Ltd Process
DE202014105749U1 (de) * 2014-11-27 2015-01-09 iCradle GmbH Daumenschalter zur Befestigung an einem Fahrradlenker und über einen derartigen Daumenschalter bedienbares Steuersystem für ein Fahrrad
WO2017078947A1 (en) * 2015-10-21 2017-05-11 Cambryn Biologics, Llc Processes for purifying proteins from plasma
EP3558362A1 (en) 2016-12-20 2019-10-30 CSL Behring AG Methods for affecting salmonella infections
EP3684818A2 (en) 2017-09-21 2020-07-29 UMC Utrecht Holding B.V. Anti-gd2 antibody for the treatment of neuroblastoma
WO2019219890A1 (en) * 2018-05-17 2019-11-21 Csl Behring Ag Method and system of protein extraction
KR102875179B1 (ko) 2018-11-30 2025-10-23 체에스엘 베링 아게 폴리클로날 면역글로불린을 사용한 급성 악화를 예방하거나 치료하기 위한 방법 및 조성물
CN114096559B (zh) 2019-03-27 2026-03-20 蒂嘉特克斯公司 工程化iga抗体及其使用方法
CN112574296B (zh) * 2020-12-30 2023-05-19 中国医学科学院输血研究所 一种模拟IVIg的多人份混合人血浆IgG样品的分离纯化方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5500345A (en) * 1989-04-25 1996-03-19 Iatron Laboratories, Inc. Hybridomas producing monoclonal antibodies specific for C-reactive protein and methods for detection of C-reactive protein
DE3927111C3 (de) 1989-08-17 1994-09-01 Biotest Pharma Gmbh Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate
US5258177A (en) * 1991-12-10 1993-11-02 Alpha Therapeutic Corporation IgA preparation and process of making the same
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
CA2167835A1 (en) 1993-07-30 1995-02-09 Richard A. Weltzin Monoclonal iga antibody against respiratory syncytial virus
DE19600939C1 (de) 1996-01-12 1997-08-28 Immuno Ag Verfahren zur Trennung von IgG und IgA
EP0839915A1 (en) 1996-11-01 1998-05-06 Institut Suisse De Recherches Experimentales Sur Le Cancer Isrec Secretory immunoglobulin A as a mucosal vaccine delivery system
WO1998057993A1 (en) 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
US20020114802A1 (en) 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
IL140155A (en) 1998-06-09 2005-12-18 Statens Seruminstitut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
JP2000103800A (ja) 1998-09-29 2000-04-11 Yoshitomi Pharmaceut Ind Ltd 免疫グロブリンａの精製方法
AUPP806999A0 (en) * 1999-01-08 1999-02-04 Csl Limited Process for purifying immunoglobulins
EP1068871A1 (en) 1999-07-07 2001-01-17 Jean-Paul Perraudin Novel methods and medicament for treating infections diseases involving microbial biofilms
AU2234801A (en) 1999-12-13 2002-04-29 Universidad Nacional Autonoma De Mexico Immunoenzymatic quantification method
NZ527977A (en) 2001-02-12 2005-10-28 Medarex Inc Human monoclonal antibodies to FC alpha receptor (CD89)
US6932967B2 (en) 2001-03-22 2005-08-23 Michael R. Simon Human medical treatment by aerosol inhalation of immunoglobulin A
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
US20060165675A1 (en) 2002-08-02 2006-07-27 Richman-Eisenstat Janice Beth Modulation of mesenchymal cells via iga-receptors
ES2383300T3 (es) 2003-11-13 2012-06-20 Hanmi Holdings Co., Ltd Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación
US8119104B2 (en) 2006-12-13 2012-02-21 Michael R. Simon Treatment of celiac disease with IgA
US8709413B2 (en) 2006-12-13 2014-04-29 Michael R. Simon Treatment of celiac disease with IgA
US7597891B2 (en) 2006-12-13 2009-10-06 Simon Michael R Synthesis of human secretory IgA for the treatment of Clostridium difficile associated diseases
US8021645B2 (en) 2006-12-13 2011-09-20 Simon Michael R Synthesis of human secretory IgA and IgM and the formation of a medicament therefrom
US8313730B2 (en) 2006-12-13 2012-11-20 Michael R. Simon Treatment of celiac disease with IgA
US20080145420A1 (en) 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
US7794721B2 (en) 2006-12-13 2010-09-14 Simon Michael R Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
CN102124027B (zh) 2008-05-15 2015-01-21 温氏健康有限公司 产生富含分泌型免疫球蛋白的乳组分的方法
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
EP2465536A1 (en) 2010-12-14 2012-06-20 CSL Behring AG CD89 activation in therapy
WO2013122834A1 (en) * 2012-02-14 2013-08-22 Bio-Rad Laboratories, Inc. REDUCING pH EXCURSIONS IN ION EXCHANGE CHROMATOGRAPHY
EP2636683A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Treatment of mucositis with Immunoglobulin
BR112014022240A2 (pt) 2012-03-09 2017-08-01 Csl Behring Ag composições compreendendo imunoglobulinas semelhantes à secretoras
EP2636684A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
WO2013158279A1 (en) * 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species

Also Published As

Publication number Publication date
EP2636681A1 (en) 2013-09-11
EP2822965A1 (en) 2015-01-14
EP2822965B1 (en) 2022-05-11
JP6259777B2 (ja) 2018-01-10
HK1202881A1 (en) 2015-10-09
AU2013201388A1 (en) 2013-09-26
CN104245728A (zh) 2014-12-24
KR20140136028A (ko) 2014-11-27
CN104245728B (zh) 2017-11-28
ES2919861T3 (es) 2022-07-28
JP2015509523A (ja) 2015-03-30
AU2013201388B2 (en) 2015-09-03
US9828418B2 (en) 2017-11-28
WO2013132053A1 (en) 2013-09-12
KR102079487B1 (ko) 2020-02-21
US20150005476A1 (en) 2015-01-01

Similar Documents

Publication Publication Date Title
DK3454346T3 (da) Anordning til cylotronfremstilling af technetium-99m
DK2822965T3 (da) FREMGANGSMÅDE TIL BERIGELSE AF IgA
DK2906696T4 (da) Fremgangsmåder til modulering af c9orf72-ekspression
DK3725778T4 (da) Formuleringer af enzalutamid
DK3225604T3 (da) Fremgangsmåde til fremstilling af flerlagsruder
DK2730878T3 (da) Pladestak og fremgangsmåde til fremstilling af en pladestak
DK3824991T3 (da) Fremgangsmåde til forberedelse af lithiumsulfat
DK2934251T3 (da) Indretning til fremstilling af mælkeskum
DK2895156T3 (da) Fremgangsmåde til fremstilling af terapeutiske nanopartikler
DK3689853T3 (da) Fremgangsmåde til syntese af thyreoideahormonanaloger og polymorfer deraf
DK2718404T3 (da) Fremgangsmåde til fremstilling af flydende carbonhydrider
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
DK2623288T3 (da) Fremgangsmåde til fremstilling af formstøbte skumdele
DK2874506T3 (da) Fremgangsmåde til fremstilling af enzymgranulater
DK2836460T3 (da) Fremgangsmåde til fremstilling af graphen
DK2882444T3 (da) Mikroporøs zirconiumsilikat til behandling af hyperkaliæmi
DK2953904T3 (da) Fremgangsmåde til kontrolleret fremstilling af et biocid
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK2931313T3 (da) Opløsningsformuleringer af manipulerede anti-il-23p19-antistoffer
DK3680000T3 (da) Fremgangsmåder til oprensning af antistoffer
DK2728009T3 (da) Fremgangsmåde til fremstilling af monosaccharider
DK2919777T3 (da) Transmukosal afgivelse af tocotrienol
DK2985275T3 (da) Fremgangsmåde til oprensning af beta-hydroxy-beta-methylsmørsyre
DK2906219T3 (da) Orvepitant til behandling af kronisk pruritus
DK2809782T3 (da) Forbedret fremgangsmåde til fremstilling af makrokugler